Axplora
Raubling, Germany
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Axplora
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Raubling, Germany
- Modalities
- Small Molecule API, HPAPI / High-Potency API, Steroids / Corticosteroids, ADC Payload / Linker, Oligonucleotide / Peptide (purification), Preparative Chromatography, Flow Chemistry, Hazardous Chemistry, Lyophilization
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Axplora
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesSmall Molecule API, HPAPI / High-Potency API, Steroids / Corticosteroids, ADC Payload / Linker, Oligonucleotide / Peptide (purification), Preparative Chromatography, Flow Chemistry, Hazardous Chemistry, Lyophilization
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (9 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (9 modalities)
Recent News 10 articles
Axplora Group announces €50m expansion of GLP-1 manufacturing site - European Biotechnology Magazine
Axplora Expands Farmabios Site in Gropello Cairoli - Contract Pharma
CDMO Axplora to pump $60M into Italian complex API plant - Fierce Pharma
CDMO Axplora reveals €50M expansion at French production site - Fierce Pharma
CDMO Axplora bets €50M on ADC and GLP-1 growth - BioProcess International
Axplora Repositions European Site on High-Potency Drugs as India Takes Over UDCA Production - CHEManager
Axplora Adding New Facility for Purification of Peptides, Other APIs - DCAT Value Chain Insights
Axplora expands Le Mans manufacturing site to support increased ADC demand - BioProcess International
Axplora To Double Its Manufacturing Capacity In Italy With Expansion - Pharmaceutical Online
Major Announcements for Axplora - The Medicine Maker
Frequently Asked Questions About Axplora
What is Axplora's CDMO Signal Score?
Axplora has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Axplora for a manufacturing program?
Use the free AI matchmaker to compare Axplora against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
SEQENS Pharmaceutical Solutions (broader group)
Écully, France
Small Molecule API, HPAPI, Pharmaceutical Intermediates, Specialty Ingredients, Flow Chemistry, Biocatalysis, Photochemistry
Novasep
Lyon, France
Small Molecule API, HPAPI / High-Potency API, ADC (Antibody-Drug Conjugate), Lentiviral Vector, Biologics (Recombinant Proteins, mAbs), Oligonucleotide, Peptide, Chromatography / Purification Services
Fresenius Kabi
Bad Homburg, Germany
Biologics (Sterile Injectables), Monoclonal Antibody, Biosimilars, Small Molecule API, HPAPI / Oncology Injectables, mRNA, Cell Therapy (equipment/processing platform), Sterile Fill-Finish, Compounding (outsourcing facility)
Olon Group
Rodano (Milan), Italy
Small Molecule API, HPAPI / Cytotoxics, Microbial Fermentation, Mammalian Cell Culture, Recombinant Proteins / Enzymes, Biologics (mAbs), ADC (end-to-end bioconjugation), Oligonucleotide / Peptide, Chemical Synthesis, Semi-Synthesis
Fermion (Orion Group)
Espoo, Finland
Small Molecule API, HPAPI, Semi-solid drug product (creams, gels, ointments), Hormonal products